{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:39:38Z","timestamp":1793547578221,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.seizure.2021.07.012","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T12:15:22Z","timestamp":1626178522000},"page":"339-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials"],"prefix":"10.1016","volume":"91","author":[{"given":"Yuyi","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhi","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.seizure.2021.07.012_bib0001","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMe1913775","article-title":"Management of Established Status Epilepticus","volume":"381","author":"Smith","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.seizure.2021.07.012_bib0002","first-page":"615","volume":"14","author":"Betjemann","year":"2015","journal-title":"Status epilepticus in adults"},{"issue":"9971","key":"10.1016\/j.seizure.2021.07.012_bib0003","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: new advances","volume":"385","author":"Mosh\u00e9","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.seizure.2021.07.012_bib0004","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa002141","article-title":"A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus","volume":"345","author":"Alldredge","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.seizure.2021.07.012_bib0005","article-title":"Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children","author":"Appleton","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.seizure.2021.07.012_bib0006","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMoa1107494","article-title":"Intramuscular versus intravenous therapy for prehospital status epilepticus","volume":"366","author":"Silbergleit","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.seizure.2021.07.012_bib0007","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jama.2014.2625","article-title":"Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial","volume":"311","author":"Chamberlain","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.seizure.2021.07.012_bib0008","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-Based Guideline: treatment of Convulsive Status Epilepticus in Children and Adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"issue":"4","key":"10.1016\/j.seizure.2021.07.012_bib0009","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2017.4382","article-title":"Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus","volume":"75","author":"Ga\u00ednza-Lein","year":"2018","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.seizure.2021.07.012_bib0010","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM199809173391202","article-title":"A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group","volume":"339","author":"Treiman","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.seizure.2021.07.012_bib0011","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/PEC.0b013e318188fcac","article-title":"Anticonvulsant medications in the pediatric emergency room and intensive care unit","volume":"24","author":"Abend","year":"2008","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.seizure.2021.07.012_bib0012","series-title":"Rapid response report NPSA\/2010\/RRR018: preventing fatalities from medication loading doses","year":"2010"},{"key":"10.1016\/j.seizure.2021.07.012_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","article-title":"Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam\u2013Pilot study","volume":"114","author":"Mundlamuri","year":"2015","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.seizure.2021.07.012_bib0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: a 30-Year Longitudinal Cohort Study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2021.07.012_bib0015","series-title":"Epilepsies: diagnosis and management. clinical guideline [CG137]","year":"2020"},{"issue":"10231","key":"10.1016\/j.seizure.2021.07.012_bib0016","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0140-6736(20)30674-7","article-title":"Second-line anticonvulsants for paediatric convulsive status epilepticus","volume":"395","author":"Appleton","year":"2020","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.seizure.2021.07.012_bib0017","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1001\/jama.2008.890","article-title":"FDA: epilepsy drugs may carry skin risks for Asians","volume":"300","author":"Kuehn","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.seizure.2021.07.012_bib0018","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.seizure.2013.10.004","article-title":"Gaps and opportunities in refractory status epilepticus research in children: a multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG)","volume":"23","author":"S\u00e1nchez Fern\u00e1ndez","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.07.012_bib0019","doi-asserted-by":"crossref","first-page":"g254","DOI":"10.1136\/bmj.g254","article-title":"Drug treatment of epilepsy in adults","volume":"348","author":"Schmidt","year":"2014","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.seizure.2021.07.012_bib0020","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.pcl.2017.08.007","article-title":"Drug Treatment of Seizures and Epilepsy in Newborns and Children","volume":"64","author":"Dang","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.seizure.2021.07.012_bib0021","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fphar.2020.00527","article-title":"Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care","volume":"11","author":"Sung","year":"2020","journal-title":"Front Pharmacol"},{"issue":"22","key":"10.1016\/j.seizure.2021.07.012_bib0022","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"issue":"10186","key":"10.1016\/j.seizure.2021.07.012_bib0023","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet"},{"issue":"10186","key":"10.1016\/j.seizure.2021.07.012_bib0024","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"issue":"10231","key":"10.1016\/j.seizure.2021.07.012_bib0025","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial","volume":"395","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.seizure.2021.07.012_bib0026","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13312-020-1755-4","article-title":"Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: a Randomized Double-blind Controlled Clinical Trial","volume":"57","author":"Vignesh","year":"2020","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.seizure.2021.07.012_bib0027","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2017.05.001","article-title":"Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study","volume":"49","author":"Gujjar","year":"2017","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2021.07.012_bib0028","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","article-title":"Clinical Efficacy and Safety of Injectable Levetiracetam Versus Phenytoin as Second-Line Therapy in the Management of Generalized Convulsive Status Epilepticus in Children: an Open-Label Randomized Controlled Trial","volume":"15","author":"Noureen","year":"2019","journal-title":"J Clin Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2021.07.012_bib0029","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","article-title":"Levetiracetam versus phenytoin in management of status epilepticus","volume":"22","author":"Chakravarthi","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"7","key":"10.1016\/j.seizure.2021.07.012_bib0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12098-020-03221-2","article-title":"Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus","volume":"87","author":"Nalisetty","year":"2020","journal-title":"Indian J Pediatr"},{"issue":"10","key":"10.1016\/j.seizure.2021.07.012_bib0031","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.4103\/jfmpc.jfmpc_750_19","article-title":"Levetiracetam versus phenytoin in children with status epilepticus","volume":"8","author":"Wani","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.seizure.2021.07.012_bib0032","first-page":"237","article-title":"Randomized controlled trial of levetiracetam versus fosphenytoin for convulsive status epilepticus in children","volume":"5","author":"C.S","year":"2018","journal-title":"Pediatric Review: International Journal of Pediatric Research"},{"issue":"9","key":"10.1016\/j.seizure.2021.07.012_bib0033","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Reprint\u2013preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"issue":"Pt 8","key":"10.1016\/j.seizure.2021.07.012_bib0034","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/brain\/awh200","article-title":"Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood","volume":"127","author":"Arts","year":"2004","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.seizure.2021.07.012_bib0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2021.07.012_bib0036","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-Resistant Epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"2","key":"10.1016\/j.seizure.2021.07.012_bib0037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"7414","key":"10.1016\/j.seizure.2021.07.012_bib0038","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.seizure.2021.07.012_bib0039","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/epi.14070","article-title":"Nonconvulsive status epilepticus in rats leads to brain pathology","volume":"59","author":"Avdic","year":"2018","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2021.07.012_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12028-012-9790-1","article-title":"Treatment of status epilepticus: an international survey of experts","volume":"18","author":"Riviello","year":"2013","journal-title":"Neurocrit Care"},{"issue":"1","key":"10.1016\/j.seizure.2021.07.012_bib0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12028-012-9711-3","article-title":"Practice variations in the management of status epilepticus","volume":"17","author":"Cook","year":"2012","journal-title":"Neurocrit Care"},{"issue":"12","key":"10.1016\/j.seizure.2021.07.012_bib0042","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneurol.2012.2203","article-title":"Substitution Monotherapy With Levetiracetam vs Older Antiepileptic Drugs: a Randomized Comparative Trial","volume":"69","author":"Hakami","year":"2012","journal-title":"Arch Neurol"},{"issue":"9566","key":"10.1016\/j.seizure.2021.07.012_bib0043","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0140-6736(07)60470-X","article-title":"First-choice drug for newly diagnosed epilepsy","volume":"369","author":"French","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.seizure.2021.07.012_bib0044","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425255.2014.876006","article-title":"The role of drug metabolizing enzymes in clearance","volume":"10","author":"Di","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.seizure.2021.07.012_bib0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrd3408","article-title":"Managing the challenge of chemically reactive metabolites in drug development","volume":"10","author":"Park","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.seizure.2021.07.012_bib0046","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd4581","article-title":"Predicting drug metabolism: experiment and\/or computation?","volume":"14","author":"Kirchmair","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.seizure.2021.07.012_bib0047","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2174\/1389200218666170607100054","article-title":"A Review on Pharmacokinetics of Levetiracetam in Neonates","volume":"18","author":"Agrawal","year":"2017","journal-title":"Curr Drug Metab"},{"issue":"11","key":"10.1016\/j.seizure.2021.07.012_bib0048","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clinical pharmacokinetics of levetiracetam"},{"key":"10.1016\/j.seizure.2021.07.012_bib0049","first-page":"725","author":"Hoofnagle","year":"2013","journal-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury"},{"issue":"3","key":"10.1016\/j.seizure.2021.07.012_bib0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/tpj.2014.86","article-title":"Pharmacogenomic information in drug labels: european Medicines Agency perspective","volume":"15","author":"Ehmann","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.seizure.2021.07.012_bib0051","article-title":"CH Topic E15: definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories","year":"2007","journal-title":"European Medicines Agency"},{"issue":"11","key":"10.1016\/j.seizure.2021.07.012_bib0052","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.seizure.2021.07.012_bib0053","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","article-title":"Drug-drug-gene interactions and adverse drug reactions","volume":"20","author":"Malki","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"10.1016\/j.seizure.2021.07.012_bib0054","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.seizure.2021.07.012_bib0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jcpt.12660","article-title":"Association of CYP2C9\u00d73 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"43","author":"Wu","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.seizure.2021.07.012_bib0056","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1517\/17425255.2015.1053463","article-title":"CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects","volume":"11","author":"Franco","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.seizure.2021.07.012_bib0057","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tox.2009.08.013","article-title":"Polymorphisms of human cytochrome P450 2C9 and the functional relevance","volume":"278","author":"Zhou","year":"2010","journal-title":"Toxicology"},{"issue":"5","key":"10.1016\/j.seizure.2021.07.012_bib0058","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/092986711794480131","article-title":"Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development","volume":"18","author":"He","year":"2011","journal-title":"Curr Med Chem"},{"issue":"7","key":"10.1016\/j.seizure.2021.07.012_bib0059","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-010-0817-2","article-title":"Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients","volume":"66","author":"Kesavan","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2021.07.012_bib0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2009.12.004","article-title":"Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy","volume":"19","author":"S\u00e1nchez","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.07.012_bib0061","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1343650","article-title":"ABCB1 Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population","volume":"2019","author":"Chouchi","year":"2019","journal-title":"Dis Markers"},{"issue":"9","key":"10.1016\/j.seizure.2021.07.012_bib0062","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2217\/14622416.8.9.1151","article-title":"Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses","volume":"8","author":"Hung","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.seizure.2021.07.012_bib0063","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/tan.13530","article-title":"HLA-associated antiepileptic drug-induced cutaneous adverse reactions","volume":"93","author":"Mullan","year":"2019","journal-title":"Hla"},{"issue":"12","key":"10.1016\/j.seizure.2021.07.012_bib0064","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2021.07.012_bib0065","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.seizure.2021.07.012_bib0066","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cpt.1190","article-title":"HLA Alleles and CYP2C9\u00d73 as Predictors of Phenytoin Hypersensitivity in East Asians","volume":"105","author":"Su","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2021.07.012_bib0067","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2020.06.004","article-title":"Stevens-Johnson syndrome triggered by Levetiracetam-Caution for use with Carbamazepine","volume":"80","author":"Sawal","year":"2020","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.seizure.2021.07.012_bib0068","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200812","article-title":"HLA-A*11:01 is associated with levetiracetam-induced psychiatric adverse events","volume":"13","author":"Yang","year":"2018","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.seizure.2021.07.012_bib0069","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1528-1167.2012.03603.x","article-title":"Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam","volume":"54","author":"Helmstaedter","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.07.012_bib0070","unstructured":"WHO Toxicity Grading Scale for Determining The Severity of Adverse Events. 2003."}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:02:25Z","timestamp":1761012145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121002429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":70,"alternative-id":["S1059131121002429"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.07.012","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}